A company centered on treatments and diagnostics for misfolded proteins diseases.

Amorfix Life Sciences indicators sale and distribution contract with Cedarlane Laboratories Amorfix Life Sciences, a company centered on treatments and diagnostics for misfolded proteins diseases, announced today that it has signed an agreement with Cedarlane Laboratories for the sale and distribution of Amorfix’s proprietary antibodies and reagents. Amorfix has developed the world’s most sensitive diagnostic assays for variant Creutzfeldt-Jakob Disease and for aggregated Abeta, the sign of Alzheimer’s Disease . Consequently, we’ve received several inquiries from investigators involved with protein misfolding studies for our reagents, said Dr haldol depot . George Adams, CEO of Amorfix.

mechanism of action

We expect to initiate our pet model proof of concept studies in the first calendar quarter of following yr. Related StoriesNew RNA test of blood platelets may be used to detect area of cancerCornell biomedical engineers develop 'super organic killer cells' to destroy cancers cells in lymph nodesOvarian malignancy patients with a history of oral contraceptive make use of have better outcomesPrion Proteins and Cancer The expression of regular cellular PrP on human peripheral bloodstream mononuclear cells was first recognized by Dr. Neil Cashman, CSO of Amorfix, who later also found that a portion of these protein molecules were partially misfolded as dependant on the exposure of DSEs.